In the RATIONALE 305 trial, tislelizumab combined with chemotherapy prolonged overall survival for patients with PD-L1 expression
Additional follow-up is needed to assess overall survival benefits in intention-to-treat patient population
Safety findings of tislelizumab were consistent with that observed in previous trials
https://finance.yahoo.com/news/beigene-announces-positive-findings-phase-100000175.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.